Company Overview
| Stock Name | Giant Biogene |
|---|---|
| Stock Code | 02367 |
| Company Full Name | To be extracted |
| Industry | Healthcare |
| Principal Activities | 我們是中國基於生物活性成分的專業皮膚護理產品行業的領軍者,設計、開發和生產以重組膠原蛋白為關鍵生物活性成分的專業皮膚護理產品,亦開發和生產基於稀有人參皂苷技術的保健食品。 |
| Listing Date | 2022-11-04 |
| Listing Rules Era | Old Rules |
| Listing Rules Chapter | To be extracted |
| Weighted Voting Rights (WVR) | No |
| Registered Address (Mainland China) | 中國陝西省西安市長安區上林苑七路1855號 |
| Business Address (Hong Kong) | 香港九龍觀塘道348號宏利廣場5樓 |
| Place of Incorporation | To be extracted |
| Listing Method | To be extracted |
| Listing Board | Main Board |
| Website | www.xajuzi.com |
| Share Registrar | 卓佳证券登记有限公司 (Tricor Investor Services Limited) |
| Registrar Contact | (852)2980 1333 |
| A-Share/US Dual Listing | No |
Offering Information
| Offering Mechanism | Mechanism A |
|---|---|
| Offer Price | HK$ 24.30 / shares |
| Offer Price Range | Final offer price only, no range |
| Lot Size | 200 shares |
| Entry Threshold | HK$ 4,860 |
| Par Value | To be extracted |
| Offer Period | 2022-10-25 to 2022-10-28 |
| Global Offering Shares | 22,608,800 shares |
| HK Public Offer Shares (Initial) | 2,261,200 shares (10.0%) |
| Public Offer Lots (Initial) | 11,306lots (Pool A5,653lots,Pool B5,653lots) |
| International Placing Shares (Initial) | 20,347,600 shares (90.0%) |
| Offer Ratio | ~10.0% |
| Total Shares Post-IPO | 991,608,800 shares |
| Greenshoe (Over-allotment Option) | Yes |
| Stabilizing Manager (Greenshoe) | To be extracted |
| Cornerstone Share | No cornerstone investors |
| Clawback Tiers | To be extracted |
| Reallocation Option | Yes |
| Total Global Offering Size | HK$ 549,393,840 |
Subscription Tiers
Minimum subscription unit: 1 lot. Subscription amount ≤ HK$5,000,000 is Pool A, > HK$5,000,000 is Pool B.
Pool A
| Lots Subscribed | Shares Subscribed | Subscription Amount (HKD) |
|---|---|---|
| 1 lots | 200 | HK$ 4,860 |
| 2 lots | 400 | HK$ 9,720 |
| 3 lots | 600 | HK$ 14,580 |
| 4 lots | 800 | HK$ 19,440 |
| 5 lots | 1,000 | HK$ 24,300 |
| 6 lots | 1,200 | HK$ 29,160 |
| 7 lots | 1,400 | HK$ 34,020 |
| 8 lots | 1,600 | HK$ 38,880 |
| 9 lots | 1,800 | HK$ 43,740 |
| 10 lots | 2,000 | HK$ 48,600 |
| 15 lots | 3,000 | HK$ 72,900 |
| 20 lots | 4,000 | HK$ 97,200 |
| 25 lots | 5,000 | HK$ 121,500 |
| 30 lots | 6,000 | HK$ 145,800 |
| 35 lots | 7,000 | HK$ 170,100 |
| 40 lots | 8,000 | HK$ 194,400 |
| 45 lots | 9,000 | HK$ 218,700 |
| 50 lots | 10,000 | HK$ 243,000 |
| 75 lots | 15,000 | HK$ 364,500 |
| 100 lots | 20,000 | HK$ 486,000 |
| 125 lots | 25,000 | HK$ 607,500 |
| 150 lots | 30,000 | HK$ 729,000 |
| 175 lots | 35,000 | HK$ 850,500 |
| 200 lots | 40,000 | HK$ 972,000 |
| 225 lots | 45,000 | HK$ 1,093,500 |
| 250 lots | 50,000 | HK$ 1,215,000 |
| 300 lots | 60,000 | HK$ 1,458,000 |
| 350 lots | 70,000 | HK$ 1,701,000 |
| 450 lots | 90,000 | HK$ 2,187,000 |
| 500 lots | 100,000 | HK$ 2,430,000 |
Stock Connect Inclusion Analysis
| Avg Daily HK Mkt Cap | HK$ 28.64B |
|---|---|
| Analysis Result | Already included in Stock Connect (both) |
Valuation & Financials
| Market Cap (at Offer Price) | HK$ 24,096,093,840 |
|---|---|
| Pre-IPO Valuation (Last Round) | Not disclosed |
| P/E Ratio | Not disclosed |
| Profit/Loss Status | 盈利約人民幣828.1百萬元 |
| Period-End Cash Balance | 人民幣71.03億元 |
| Listing Expenses | To be extracted |
| Listing Expenses / Funds Raised | To be extracted |
| Total Pre-IPO Investment | To be extracted |
Financial Data
Unit:
'000
RMB
Income Statement
| Item | 2019 | 2020 | 2021 |
|---|---|---|---|
| Revenue | 956,702 | 1,190,479 | 1,552,486 |
| Cost of sales | -159,990 | -183,410 | -198,149 |
| Gross profit | 796,712 | 1,007,069 | 1,354,337 |
| Other income and gains, net | 31,166 | 21,386 | 33,155 |
| Selling and distribution expenses | -93,788 | -158,422 | -346,211 |
| Administrative expenses | -28,845 | -32,992 | -72,274 |
| Profit before tax | 676,996 | 973,242 | 972,917 |
| Income tax expense | -101,816 | -146,757 | -144,785 |
| Profit for the year | 575,180 | 826,485 | 828,132 |
| Profit attributable to owners | 552,260 | 826,450 | 828,132 |
Balance Sheet
| Item | 2019 | 2020 | 2021 |
|---|---|---|---|
| Cash and cash equivalents | 72,323 | 367,805 | 7,103,000 |
| Trade and bills receivables | 17,260 | 54,523 | 65,639 |
| Inventories | 50,863 | 64,656 | 89,394 |
| Total current assets | 1,458,255 | 2,284,098 | 7,441,322 |
| Total current liabilities | 626,054 | 2,173,890 | 6,843,042 |
| Total equity | 1,151,449 | 458,003 | 1,016,811 |
| Equity attributable to owners | 1,147,698 | 458,003 | 1,016,811 |
Cash Flow Statement
| Item | 2019 | 2020 | 2021 | 2022-05 |
|---|---|---|---|---|
| Net cash from operating activities | 656,457 | 834,124 | 692,401 | |
| Net cash from investing activities | -589,846 | -521,119 | 1,563,266 | |
| Net cash from financing activities | -2,164 | -17,523 | 4,475,544 | |
| Net increase in cash | 64,447 | 295,482 | 6,731,211 | |
| Depreciation of PP&E | 16,135 | 18,788 | 20,111 | 9,327 |
| Depreciation of right-of-use assets | 673 | 867 | 868 | 830 |
| Amortisation of intangible assets | 1,074 | 1,197 | 1,314 | 586 |
| Purchase of PP&E | -85,473 | -75,506 | -74,999 | -33,097 |
Income Statement
Balance Sheet
Cash Flow Statement
Source: Accountants' Report and Audited Consolidated Financial Statements
| First Day Close | HK$ 26.7 |
|---|---|
| First Day Open | HK$ 26.0 |
| First Day Change | 9.88% |
| First Day Volume | 7243000.0 |
| First Day Turnover | 202303000.0 |
| Use of Proceeds | 1、約11%的所得款項凈額(即54.5百萬港元)用于研發投資以通過招聘擴大我們的研發團隊、擴展我們的研發設施及進行測試和驗證研究;
2、約28%的所得款項凈額(即138.8百萬港元)用于擴展與我們的產品組合及生物活性成分有關的生產能力;
3、約46%的所得款項凈額(即228.1百萬港元),用于增強我們的全渠道銷售及經銷網絡,并開展以科學和知識為導向的營銷活動以提高我們的品牌知名度;
4、約5%的所得款項凈額(即24.8百萬港元)用于提升我們運營及信息系統;
5、約10%的所得款項凈額(即49.6百萬港元)用作營運資金及一般公司用途。 |
Underwriting Syndicate
Joint Sponsors (2)
Overall Coordinators (2)
Joint Bookrunners (3)
Joint Lead Managers (6)
Cornerstone Investors
This stock has no cornerstone investors.
Directors & Management
| Position | Chinese name | English Name |
|---|---|---|
| Chairman | 嚴建亞 | — |
| Company Secretary | 嚴鈺博、姚淑嫻 | — |
No director data available.
Major Shareholders
| Major Shareholders & Holdings | 范博士通過Juzi Holding、Healing Holding及GBEBT Holding合共持有約60.61%投票權;嚴建亞先生為范博士配偶,亦構成控股股東。 |
|---|




